Sep 26, 2023 7:00 am EDT Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation
Sep 6, 2023 7:00 am EDT Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aug 3, 2023 7:00 am EDT Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates
Jun 26, 2023 7:00 am EDT Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma
May 22, 2023 7:00 am EDT Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board
May 10, 2023 7:00 am EDT Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference
